GlassScriptPhysician profile
Jami Jo Dowell
NPI 1194295907
$1,419.54
in general payments reported to CMS, 2019-2025
20 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $289 · 2023: $131 · 2024: $316 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809 · Education: $46.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.31 |
| Education | $46.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $308.31 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $216.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $200.84 | 2021-2025 | |
| Philips North America LLC | $118.73 | 2024 | (Ck7) Extended Holter |
| Janssen Pharmaceuticals, INC | $87.69 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $75.95 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $67.61 | 2022-2023 | |
| Novo Nordisk INC | $54.51 | 2021-2022 | |
| Stryker Corporation | $47.44 | 2025 | Variax, Augment Injectable, Fixos |
| Merck Sharp & Dohme LLC | $42.72 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $38.20 | 2023-2024 | Edarbi, Edarbi |
| Mylan Specialty L.P. | $26.10 | 2021-2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.18 | 2025 | Caplyta |
| Lundbeck LLC | $23.27 | 2025 | Rexulti |
| Astellas Pharma US INC | $22.39 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $18.10 | 2021 | |
| Biogen, INC. | $15.75 | 2021 | |
| Pfizer INC. | $13.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.56 | 2025 | Camzyos |
| Genentech USA, INC. | $4.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.